 Shares of MediciNova NASDAQ: MNOV jumped over 65 today after the company announced a collaboration with BioComo and Mie University to develop a vaccine against SARS-CoV-2. The technology platform has been used to develop experimental vaccines against Ebola virus and respiratory syncytial virus RSV. Under the agreement, MediciNova will gain exclusive worldwide development rights to use the vector technology for an experimental SARS-CoV-2 vaccine. 